Duo Is Using AI To Identify GPCR Targets Across Multiple Disease Areas

Executive Summary

Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.

Source Link: Click Here